INVA - Innoviva, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.95
-0.75 (-4.78%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close15.70
Open15.70
Bid14.37 x 800
Ask15.55 x 900
Day's range14.94 - 15.75
52-week range11.47 - 17.99
Volume854,865
Avg. volume705,556
Market cap1.518B
Beta1.61
PE ratio (TTM)10.12
EPS (TTM)1.48
Earnings date23 Oct 2018 - 29 Oct 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend date2015-09-08
1y target est15.00
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/ vilanterol ‘FF/UMEC/VI’) in a broader group of patients with moderate to severe chronic obstructive pulmonary disease (COPD) and that labelling, if approved, will be updated to further reflect its effect on exacerbations of COPD. It would also reference the effect on exacerbations based on data from the InforMing the PAthway of COPD Treatment (IMPACT) study. Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said, “Many patients with COPD continue to experience exacerbations despite taking dual bronchodilator therapies.

  • GlobeNewswire27 days ago

    Report: Exploring Fundamental Drivers Behind Allscripts Healthcare Solutions, Dean Foods, Alder BioPharmaceuticals, Innoviva, Chegg, and TEGNA — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allscripts ...

  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realistlast month

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Analysts Remain Bullish on Nektar Stock in August
    Market Realistlast month

    Analysts Remain Bullish on Nektar Stock in August

    Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.

  • Business Wire2 months ago

    Innoviva Reports Second Quarter 2018 Financial Results

    BRISBANE, Calif.-- -- Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017. Net income attributable to Innoviva stockholders increased 55.4% from the second quarter of 2017 to $54.6 million, or $0.49 per diluted share. The Company intends to prepay $110 million of its Term B Loan. Innoviva, Inc. today reported financial results for the second quarter ended June 30, ...

  • Innoviva And Other Great Growth Stocks
    Simply Wall St.3 months ago

    Innoviva And Other Great Growth Stocks

    Analysts are bullish on these following companies: Innoviva, Jazz Pharmaceuticals, Cardlytics. These companies are relatively strong financially, and have a great outlook in terms of profits and cash flow. AnalysingRead More...

  • GlobeNewswire3 months ago

    Recent Analysis Shows Church & Dwight Co., Innoviva, PTC Therapeutics, KBR, Murphy Oil, and F.N.B. Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Church ...

  • 3 Top Healthcare Stocks to Buy in June
    Motley Fool3 months ago

    3 Top Healthcare Stocks to Buy in June

    These three mid-cap healthcare stocks could be your prescription for profits.

  • The Cheapest Drug Stocks to Buy Right Now
    Motley Fool3 months ago

    The Cheapest Drug Stocks to Buy Right Now

    All three of these bargains have forward P/E ratios of less than eight.

  • Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan
    Zacks4 months ago

    Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

    Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

  • Business Wire4 months ago

    GSK Submits Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD

    GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for once-daily fluticasone furoate/umeclidinium/vilanterol under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease .

  • Business Wire4 months ago

    Innoviva Names Geoffrey Hulme as Interim Principal Executive Officer

    Innoviva, Inc. (INVA) (“Innoviva”) today announced the appointment of Geoffrey Hulme as interim Principal Executive Officer effective May 21, 2018. Mr. Hulme has a 25 year career in finance and investment management with a record of creating and maximizing shareholder value. Prior to joining Innoviva, Mr. Hulme served as the owner and manager of Steel Valley Capital LLC and Steel Valley Advisors LLC, a Registered Investment Adviser.

  • Associated Press5 months ago

    Innoviva: 1Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 35 cents per share. The biopharmaceutical ...

  • Business Wire5 months ago

    Innoviva Reports First Quarter 2018 Financial Results

    Innoviva, Inc. today reported financial results for the first quarter ended March 31, 2018.

  • Business Wire5 months ago

    Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms. The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.

  • Business Wire5 months ago

    Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD

    A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.

  • Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta
    Investor's Business Daily6 months ago

    Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta

    GlaxoSmithKline[ticker symb=GSK] partner Innoviva[ticker symb=INVA] is trying to buck the market correction and finish a new base.  The biotech stock recently received new European Union approval for Relvar Ellipta, an asthma drug Innoviva developed with GSK. Last month, London-based GSK and California-based Innoviva announced that the European Commission approved a label upgrade for Relvar Ellipta. Known as Breo Ellipta in...

  • Business Wire7 months ago

    GSK Announces Positive EU Approval for Labelling Update to Relvar Ellipta in Patients with Asthma

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.

  • New Strong Sell Stocks for February 21st
    Zacks7 months ago

    New Strong Sell Stocks for February 21st

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Business Wire7 months ago

    GSK Submits Landmark IMPACT Data to European Medicines Agency to Support Expanded Label for Trelegy Ellipta

    GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease .

  • Why Innoviva Inc. Stock Jumped Tuesday
    Motley Fool7 months ago

    Why Innoviva Inc. Stock Jumped Tuesday

    An activist hedge fund is shaking things up at Innoviva.

  • PR Newswire7 months ago

    Sarissa Capital Reconstitutes Innoviva Board Of Directors

    Follows Termination of CEO Mike Aguiar GREENWICH, Conn. , Feb. 13, 2018 /PRNewswire/ -- Sarissa Capital Management LP announced today that Sarissa Capital has entered into an agreement with Innoviva, Inc. ...

  • Associated Press7 months ago

    Innoviva beats Street 4Q forecasts

    The Brisbane, California-based company said it had profit of 45 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...